Patents by Inventor Christel Larbouret
Christel Larbouret has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11001634Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.Type: GrantFiled: May 2, 2016Date of Patent: May 11, 2021Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIERInventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
-
Patent number: 10398774Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.Type: GrantFiled: December 8, 2015Date of Patent: September 3, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIERInventors: Bruno Robert, Christel Larbouret, Pierre Martineau, Marie-Alix Poul
-
Publication number: 20190153104Abstract: The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.Type: ApplicationFiled: April 28, 2017Publication date: May 23, 2019Inventors: EUGENE ZHUKOVSKY, OLIVIER LEGER, PIERRE-EMMANUEL GERARD, ANDRE PELEGRIN, CHRISTEL LARBOURET
-
Patent number: 10196455Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.Type: GrantFiled: November 7, 2013Date of Patent: February 5, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Institut Regional du Cancer de MontpellierInventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
-
Publication number: 20180291098Abstract: The disclosure relates to human anti-NRG1 neutralizing monoclonal antibodies that do not interfere with the NRG1 binding to the HER3 receptor and uses thereof. More particularly, an isolated human monoclonal antibody comprising a heavy and light chain variable regions with specific CDRs defined by their sequences is disclosed.Type: ApplicationFiled: October 26, 2016Publication date: October 11, 2018Inventors: Charline Ogier, Christel Larbouret, Andre Pelegrin, Thierry Chardes
-
Publication number: 20180155433Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.Type: ApplicationFiled: May 2, 2016Publication date: June 7, 2018Inventors: Thierry CHARDÈS, Olivier DUBREUIL, André PELEGRIN, Christel LARBOURET, Jean-François PROST, Jean-Marc BARRET, Stéphane DEGOVE
-
Publication number: 20170340734Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.Type: ApplicationFiled: December 8, 2015Publication date: November 30, 2017Inventors: Bruno ROBERT, Christel LARBOURET, Pierre MARTINEAU, Marie-Alix POUL
-
Patent number: 9522956Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.Type: GrantFiled: November 10, 2014Date of Patent: December 20, 2016Assignee: L'Institut National de la Sante et de la Recherche MedicaleInventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
-
Publication number: 20160319033Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.Type: ApplicationFiled: November 7, 2013Publication date: November 3, 2016Inventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
-
Patent number: 9409988Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.Type: GrantFiled: June 22, 2012Date of Patent: August 9, 2016Assignees: INSERM (Institut National De La Sante Et De La Recherche Medicale), ORIBASE Pharma, UNIVERSITE De Montpellier 1, INSTITUT Regional Du Cancer De Montpellier-Val D'AurelleInventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Patent number: 9346883Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.Type: GrantFiled: May 11, 2012Date of Patent: May 24, 2016Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Gamamabs Pharma SAInventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
-
Patent number: 9249228Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.Type: GrantFiled: June 22, 2012Date of Patent: February 2, 2016Assignees: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Patent number: 9127065Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.Type: GrantFiled: May 21, 2012Date of Patent: September 8, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Val d'Aurelle—Paul Lamarque, Universite de Montpellier 1Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
-
Publication number: 20150132308Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.Type: ApplicationFiled: November 10, 2014Publication date: May 14, 2015Inventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
-
Publication number: 20140302041Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.Type: ApplicationFiled: June 22, 2012Publication date: October 9, 2014Applicants: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140227283Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.Type: ApplicationFiled: June 22, 2012Publication date: August 14, 2014Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Regional du Cancer de Montpellier-Val d'Aurelle, UNIVERSITE DE MONTPELLIER 1, OriBase PharmaInventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140141019Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.Type: ApplicationFiled: May 11, 2012Publication date: May 22, 2014Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
-
Publication number: 20140112931Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.Type: ApplicationFiled: May 21, 2012Publication date: April 24, 2014Applicants: UNIVERSITE DE MONTPELLIER 1, CENTRE VAL D'AURELLE - PAUL LAMARQUEInventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
-
Publication number: 20090214541Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.Type: ApplicationFiled: December 15, 2006Publication date: August 27, 2009Inventors: Stephen D. Gillies, David Azria, Christel Larbouret, Andre Pelegrin